Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinical impact of assay of estrogen receptor βcx in breast cancer

Abstract

Since 1996 when estrogen receptor β (ERβ) was discovered, much effort has been devoted to the question of the value of ERβ as a prognostic and/or predictive factor in breast cancer and its potential as a novel target for pharmacological intervention. When estrogen receptors are applied on sucrose gradients and quantified by ligand binding, we found that in contrast to ERa, which has a narrow tissue distribution, ERβ is expressed in many tissues including both normal and malignant breast tissue. Receptor protein levels in tissues can also be measured from the intensities of bands after Western blotting and can be quantified when purified and quantified receptor is used as a standard. With this technique, we found that there were some tumors which had over 600 fmol/mg of ERβ protein but no detectable estradiol binding. In such tumors, RT-PCR analysis revealed that ERβcx is the only ERβ isoform present. ERβcx is a splice variant which utilizes an alternative exon 8. This change in the C-terminus results in very poor binding to estradiol (E2) and has a dominant negative effect on ERa function. Imunohistochemical analysis with an ERβcx specific antibody in 115 ERa-positive breast cancers revealed that about half of the samples expressed ERβcx protein. Initial analysis of samples from patients with preoperative tamoxifen treatment revealed that ERa-positive tumors expressing ERβcx and lacking PR seemed to be resistant to the antiestrogen. We conclude that, in order to better characterize breast cancers and design appropriate therapy for individual patients, assays for ERβcx must be made available to clinicians.

This is a preview of subscription content, log in to check access.

References

  1. 1)

    Kuiper GG, Enmark E, Pelto-Huikko M,et al: Cloning of a novel estrogen receptor expressed in rat prostate and ovary.Proc Natl Acad Sci USA 93: 5925–5930, 1996.

  2. 2)

    Weihua Z, Makela S, Andersson LC,et al: A role for estrogen receptor beta in the regulation of growth of the ventral prostate.Proc Natl Acad Sci USA 98: 6330–6335, 2001.

  3. 3)

    Dotzlaw H, Leygue E, Watson PH,et al: Expression of estrogen receptor-beta in human breast tumors.J Clin Endocrinol Metab 82: 2371–2374, 1997.

  4. 4)

    Vladusic EA, Hornby AE, Guerra-Vladusic FK,et al: Expression of estrogen receptor beta messenger RNA variant in breast cancer.Cancer Res 58: 210–214, 1998.

  5. 5)

    Speirs V, Malone C, Walton DS,et al: Increased expression of estrogen receptor beta mRNA in tamoxifenresistant breast cancer patients.Cancer Res 59: 5421–5424, 1999.

  6. 6)

    Speirs V, Parkes AT, Kerin MJ,et al: Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?Cancer Res 59: 525–528, 1999.

  7. 7)

    Fuqua SA, Schiff R, Parra I,et al: Expression of wildtype estrogen receptor beta and variant isoforms in human breast cancer.Cancer Res 59: 5425–5428, 1999.

  8. 8)

    Jarvinen TA, Pelto-Huikko M, Holli K,et al: Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.Am J Pathol 156: 29–35, 2000.

  9. 9)

    Iwao K, Miyoshi Y, Egawa C,et al: Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers.Int J Cancer 88: 733–736, 2000.

  10. 10)

    Roger P, Sahla ME, Makela S,et al: Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.Cancer Res 61: 2537–2541, 2001.

  11. 11)

    Omoto Y, Inoue S, Ogawa S,et al: Clinical value of the wild-type estrogen receptor beta expression in breast cancer.Cancer Lett 163: 207–212, 2001.

  12. 12)

    Speirs V, Skliris GP, Burdall SE,et al: Distinct expression patterns of ER alpha and ER beta in normal human mammary gland.J Clin Pathol 55: 371–374, 2002.

  13. 13)

    Saunders PT, Millar MR, Williams K,et al: Expression of oestrogen receptor beta (ERbetal) protein in human breast cancer biopsies.Br J Cancer 86: 250–256, 2002.

  14. 14)

    Omoto Y, Kobayashi S, Inoue S,et al: Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers.Eur J Cancer 38: 380–386, 2002.

  15. 15)

    Jensen EV, Cheng G, Palmieri C,et al: Estrogen receptors and proliferation markers in primary and recurrent breast cancer.Proc Natl Acad Sci USA 98: 15197–15202, 2001.

  16. 16)

    Saji S, Sakaguchi H, Andersson S,et al: Quantitative analysis of estrogen receptor proteins in rat mammary gland.Endocrinology 142: 3177–3186, 2001.

  17. 17)

    Palmieri C, Cheng GJ, Saji S,et al: Estrogen receptor beta in breast cancer.Endocr Relat Cancer 9: 1–13, 2002.

  18. 18)

    Saji S, Jensen EV, Nilsson S,et al: Estrogen receptors alpha and beta in the rodent mammary gland.Proc Natl Acad Sci USA 97: 337–342, 2000.

  19. 19)

    Moore JT, McKee DD, Slentz-Kesler K,et al: Cloning and characterization of human estrogen receptor beta isoforms.Biochem Biophys Res Commun 247: 75–78, 1998.

  20. 20)

    Ogawa S, Inoue S, Watanabe T,et al: Molecular cloning and characterization of human estrogen receptor beta cx: a potential inhibitor of estrogen action in human.Nucleic Acids Res 26: 3505–3512, 1998.

  21. 21)

    Saji S, Omoto Y, Shimizu C,et al: Expression of Estrogen Receptor (ER) beta cx Protein in ER alphapositive Breast Cancer; Specific Correlation with Progesterone Receptor.Cancer Res 62: 4849–4853, 2002.

  22. 22)

    Harvey JM, Clark GM, Osborne CK,et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol 17: 1474-1481, 1999.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol 17: 1474–1481, 1999.

Download references

Author information

Correspondence to Shigehira Saji or Yoko Omoto or Chikako Shinizu or Shin-ichiro Horiguchi or Toru Watanabe or Nobuaki Funata or Shin-ichi Hayashi or Jan-Åke Gustafsson or Masakazu Toi.

Additional information

Reprint requests to Shigehira Saji Department of Surgery Breast Oncology Unit Tokyo Metropolitan Komagome Hospital, 3–1 8–22 Honkomagome, Bunkyo-ku, Tokyo 1 1 3-8677, Japan.

About this article

Cite this article

Saji, S., Omoto, Y., Shinizu, C. et al. Clinical impact of assay of estrogen receptor βcx in breast cancer. Breast Cancer 9, 303–307 (2002). https://doi.org/10.1007/BF02967608

Download citation

Key words

  • Estrogen receptor
  • Progesterone receptor
  • Breast cancer
  • Immunohistochemistry